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Abstract
Objective: In tissue engineering the material properties of synthetic compounds are chosen to enable delivery of dissociated cells
onto a scaffold in a manner that will result in in vitro formation of a new functional tissue. The seeding of human fibroblasts
followed by human endothelial cells on resorbable mesh is a precondition of a successful creation of human tissues such as vessels
or cardiac valves. Methods: Polymeric scaffolds (n18) composed of polyglycolic acid (PGA) with a fiber diameter of 12–15 mm
and a polymer density of 70 mg:ml were used as square sheets of 110.3 cm. Fibroblasts (passage 7) harvested from human
foreskin were seeded (3.4106) and cultured over a 3 week period on a PGA-mesh, followed by seeding of endothelial cells
(passage 5, 2.8106) harvested from human ascending aorta. Thereafter the new tissue was stained for HE, van Gieson,
Trichrom–Masson, Factor VIII and CD 34 and proved by scanning electron microscopy. Results: Microscopic examination of the
seeded mesh demonstrated that the human fibroblasts were attached to the polymeric fibers and had begun to spread out and
divide. The scanning electron microscopic examination demonstrated a homogeneous scaffold resembling a solid sheet of tissue.
The seeded endothelial cells formed a monolayer on the fibroblasts and no endothelial cell invasion or new formation of capillaris
could be detected. Conclusions: These results are a first step to demonstrate that seeding of human fibroblasts and endothelial cells
on PGA-mesh might be a feasible model to construct human tissues such as vessels or cardiac valves. © 1998 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Transplantation of endothelial cells onto the blood
flow surface of a small-diameter vascular conduit, ho-
mografts, or valve prosthesis to partially reproduce the
antithrombogenic lining of a naturally occuring intima
is a logical concept. In our experiences, endothelial cell
transplantation has failed to make a significant transi-
tion from the animal laboratory to the clinical arena
[1]. We believe nowadays that human endothelial cells
need a living compound for normal growth and sur-
vival in the human blood stream.
Tissue engineering is a multidisciplinary science that
utilizes basic principles from engineering and life sci-
ences to construct tissues from their cellular compo-
nents [2]. For the creation of new functional tissue three
general strategies have been adopted [3]. First, isolated
cells or cell substitutes can be used; this technique
allows the replacement of only those cells that supply
the needed function. Second, tissue-inducing substances
such as growth factors can be used to stimulate the
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growth of the desired cell population. Third, cells
can be cultured on or within specific matrices.
These days, our laboratory has focused on the cre-
ation of new functional tissue substitutes utilizing hu-
man cells attached to synthetic, biodegradable
polymer scaffolds. This approach involves isolating
cells from a donor and seeding these cells onto a
polymeric scaffold, where they attach and grow and
finally form a tissue-like structure. The cell-polymer
construct is configured to serve as a template to
guide this development. Preliminary animal studies
have demonstrated the feasibility of this strategy
with the successful formation of a tissue engineered
valve leaflet and a successful implantation of this
leaflet with good functional results [4–6]. The ability
to isolate cells types is an important component to
any tissue engineering project. Furthermore, the seed-
ing of human fibroblast followed by human endothe-
lial cells on resorbable mesh is a precondition of the
creation of any tissue in the cardio-vascular field.
2. Material and methods
2.1. Scaffold
Polymeric non-woven scaffold, composed of polyg-
lycolic acid (PGA) with a thickness of 3 mm, a fiber
diameter of 12–15 mm and a polymer density of 70
mg:ml (Albany International Research, Mansfield,
MA, USA; a kind gift from Dr. J. Vacanti, Chil-
dren’s Hospital, Harvard Medical School, Boston,
MA, USA) were used as square sheets of 0.311
cm. The PGA-polymer by hydrolysis has an in vitro
resorption rate of 4–6 weeks.
2.2. Human fibroblasts
Human foreskins were obtained from phimosisop-
erations performed at Children’s Hospital, University
Zurich. The harvested foreskins were serially washed
with phosphate buffered saline (Gibco BRL-Life
Technologie, Grand Island, NY) supplemented with
1% antibiotic:antimycotic solution saline (Gibco
BRL-Life Technologie, Grand Island, NY). Under a
laminar flood hood (Forma Scientific, Marietta, OH),
the tissue was minced into 1–2 mm pieces and
evenly distributed in 1560 mm tissue culture dishes
(Becton Dickinson, Lincoln Park, NJ). Medium was
gently added to the tissue culture dishes. Medium
consisted of Dulbecco’s modified Eagle’s medium
(Gibco BRL-Life Technologies) supplemented with
10% fetal bovine serum (Gibco BRL-Life Technolo-
gies) and 1% antibiotic:antimycoic solution (Gibco
BRL-Life Technologies). The explanted tissue was
placed in a humidified incubator (Forma scientific) at
37°C with 5% CO2 for 2–3 weeks. During this pe-
riod, the cells were migrated off the explants. There-
after cells were serially passaged to obtain sufficient
numbers of cells for cell seeding.
2.3. Human aortic endothelial cells
Human aortic endothelial cells were obtained from
the ascending aorta of the explanted sick hearts of
heart transplant patients. The harvested piece of tis-
sue of ascending aorta was serially washed with
phosphate buffered saline (Gibco BRL–Life Tech-
nologies, Grand Island, NY) supplemented with 1%
antibiotic:antimycotic solution (Gibco BRL-Life
Technologies). Under a laminar flood hood (Forma
Scientific, Marietta, OH), the intima surface was
covered with Collagenase Typ I (75 U:ml in PBS
pH 7.4, Worthington) and incubated for 30 min at
room temperature. Cells were detached using a rub-
ber cell scraper and cultured in 75 cm2 culture
dishes (Becton Dickinson Lincoln Park, NJ).
Medium 199 with EBS (Amimed, Allschwil, Switzer-
land) supplemented with 10% fetal bovine serum, 16
U:ml Heparin, 20 mg:ml Endothelial cell growth
supplement (Becton, Dickinson) and 1% antibiotic.
The explanted cells were placed in a humidified in-
cubator at 37°C with 5% CO2 for 2–3 weeks. Cells
were serially passaged to obtain sufficient numbers
of cells for cell seeding. The cells were then labeled
with an acetylated low density lipoprotein (Ac-Dil-
LDL) probe (Biomedical Technologies, Stoughton,
MA) which selectively fluorescently tags endothelial
cells through their LDL receptor. These cells popu-
lations were then checked for their purity by fluores-
cent microscopy.
2.4. Seeding
The PGA polymers (n18, 110.3 cm) were
seeded with human fibroblasts (passage 7). There
were 8–10 seeding procedures every 90 min. Each
seeding procedure contained 3.4106 human fibrob-
lasts. The seeded fibroblasts were cultured over a 21
days period. Media consisted of Dulbecco’s modified
Eagle’s medium (Gibco BRL-Life Technologies) sup-
plemented with 10% fetal bovine serum (Sigma, St.
Louis, MO) and 1% antibiotic solution (Irvine Scien-
tific, Santa Clara, CA). The medium was changed
every 4 days. Thereafter this tissue-like structure was
seeded with the pure human aortic endothelial cell
culture (passage 5, 2.8106). The constructs were
then fixed with 0.4% paraformaldehyde and stained
by conventional histological methods (Hemalaun
Eosin, Van Gieson, Trichrom-Masson) and examined
by electron microscopy.
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Fig. 1. Formation of fibroblast-polymer structure. Scanning electron
microscopy demonstrates the formation of a continuous fibroblast
tissue.
Fig. 3. Formation of endothelial monolayer. CD 34 stain demon-
strates a monolayer of endothelial cells (A) on the surface of fibro-
blasts core (B). After 4 weeks hydrolysis of polymer fibers (C) is in
process.
3. Results
3.1. Con6entional microscopy
Conventional microscopy examination demonstrated
that the seeded human fibroblasts were attached to the
polymeric fibers and had begun to spread out and
devide (Figs. 1 and 2). Furthermore the seeded cells
were forming cell bridges and a homogeneous tissue.
The production of collagen matrices was demonstrated
by staining the tissue-like structure with Van Gieson.
There was evidence of beginning hydrolytic degradation
of the polymeric fibers. The seeded endothelial cells
formed a monolayer on the human fibroblasts as
demonstrated by factor VIII and CD 34 (Fig. 3). In
addition, no invasive growth of endothelial cells or new
formation of capillaris could be detected.
3.2. Electron microscopy
The scanning electron microscopic examination 7
days before seeding with human aortic endothelial cells
demonstrated attachment of fibroblasts to the poly-
meric fibers and the formation of cell bridges between
polymeric fibers. In addition a homogeneous distribu-
tion of the seeded fibroblasts could be detected. There
was the same densitiy of fibroblasts in the upper and
lower part of the PGA mesh and no gravitiy gradient
could be detected. Some of the polymeric fibers have
started hydrolytic degradation.
4. Discussion
In tissue engineering, the material properties of syn-
thetic compounds are chosen to enable delivery of
Fig. 2. Continous formation of fibroblasts. Scanning electron mi-
croscopy shows a continuous distribution of fibroblasts throughout
the ‘polymeric architecture’ and attachment of the fibroblasts (A) to
the polymer fibers (B).
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dissociated cells into a host with successive formation
of new functional tissue. The advantage of such tissue
engineered products is the ability to grow, repair and
remodel, and no requirement for anticoagulation. Fur-
thermore, if autologous cells are used for the construc-
tion of such products, an increasing durability will be
achieved with lack of risk of immunogenicity and rejec-
tion. The new field of tissue engineering is emerging
experimentally and tissue substitutes for liver, cartilage,
bone, trachea, intestine and urologic tissue are created
[7–10]. The first tissue engineered products in clinical
use are skin replacements. In the field of cardiac
surgery tissue engineering is not unknown. Marelli et al.
demonstrated that skeletal muscle satellite cells can be
harvested, grown in vitro, and autotransplanted into
damaged heart muscle [11–13]. Preliminary results
showed that muscle formation occured at 8 weeks, but
not at 14 weeks after transplantation [12]. Apart from
that, the group of Vacanti and Mayer at Children’s
Hospital in Boston has become a leading group in
cardiovascular tissue engineering [4–6]. The goal of
their research is to create an autologous, tissue engi-
neered aortic valve with the ability to grow, repair and
remodel. They created an animal model in which a
pulmonary valve leaflet was successfully replaced by an
autologous tissue engineered valve leaflet. Furthermore
at our institution autologous capillary endothelial cells
have been harvested, grown in vitro and seeded onto
artificial vascular grafts in order to promote hemocom-
patibility [14–17]. In our experiences, endothelial cell
transplantation has failed to make a significant transi-
tion from the animal laboratory to the clinical area. We
believe nowadays that human endothelial cells need a
living compound for normal growth and survival in the
human blood stream. Since the seeding of human
fibroblasts on biodegradable mesh is a precondition of
any tissue engineered product in cardiovascular surgery
we first focused upon the development and evaluation
of an adequate method. For this reason we started with
creating a living compound of fibroblasts followed by
seeding of endothelial cells. Only endothelial cells of the
human ascending aorta were used suggesting that hu-
man capillary endothelial cells thus be angiogenetic and
might form new capillaris. For the development of a
living compound we choose preputial fibroblasts from
newborns. Since in contrast to adults this cells have a
higher potential for growth and higher cell generations
can be presumed [18]. The most important steps in this
study are the attachment of human fibroblasts to the
fibers and the formation of cell bridges and in addition
the seeding of endothelial cells forming a monolayer
with no evidence of invasion or formation of capillary
structures into the core. The polymer templates that we
utilize are both biocompatible and biodegradable; a
rapid degradation is desirable in order to minimize any
chronic foreign-body inflammatory response [19]. The
next step in our study will involve the sorting out of a
mixed cell population obtained from human ascending
aorta to pure cell populations followed by serial passag-
ing to obtain sufficient numbers of cells for cell seeding.
Cardiovascular tissue engineering has the potential to
improve our ability to treat cardiovascular disease, one
of the most important single cause of mortality in the
industrial world. The preliminary results of this study
represent a basic step on the way to construct human
cardiovascular tissue and demonstrate that the applied
technique of tissue engineering might be a feasible
approach.
References
[1] Jarrwll BE, Williams SK. Microvessel derived endothelial cell
isolation, adherence, and monolayer formation for vascular
grafts. J Vasc Surg 1991;13:733–4.
[2] Vacanti CA, Vacanti JP. Bone and cartilage reconstruction with
tissue engineering approaches. Otolaryngol Clin North Am
1994;27(1):263–76.
[3] Langer R, Vacanti JP. Tissue Eng Sci 1993;260:920–6.
[4] Zu¨nd G, Breuer CK, Shinoka T, Ma PX, Langer R, Mayer JE,
Vacanti JP. The in vitro construction of a tissue engineered
bioprosthetic heart valve. Eur J Cardio-thoracic Surg
1997;11:493–7.
[5] Shinoka T, Breuer CK, Tanel RE, Zu¨nd G, Miura T, Ma PX,
Langer R, Vacanti JP, Mayer JE. Tissue engineering heart
valves. Ann Thorac Surg 1995;60(6):513–6.
[6] Shinoka T, Ma X, Breuer CK, Cusick RA, Shum-Tim D, Zu¨nd
G, Langer R, Vacanti JP, Mayer JE. Tissue engineering heart
valves, autologous valve leaflet replacement study in a lamb
model. Circulation 1996;94(suppl II):164–8.
[7] Cao Y, Vacanti JP, Ma X, Paige KT, Upton J, Chowanski Z,
Schloo B, Langer R, Vacanti CA. Generation of neo-tendon
using synthetic polymers seeded with tendocytes. Transplant
Proc 1994;26(6):3390–1.
[8] Sakata J, Vacanti CA, Schloo B, Healy GB, Langer R, Vacanti
JP. Tracheal composites tissue engineered from chondrocytes,
trachel epithelial cells and synthetic degradable scaffolding.
Transplant Proc 1994;26(6):3309–12.
[9] Vacanti JP, Morse MA, Saltzman WM, Domb AJ, Perez-
Atayade A, Langer R. Selective cell transplantation using bioab-
sorbable artificial polymers as matrices. J Pediatr Surg
1988;23(1):3–9.
[10] Vacanti JP. Beyond transplantation: Third annual Samuael Ja-
son Mixter lecture. Arch Surg 1988;123:545–9.
[11] Greentreee D, Marelli D, Ma F, Chiu RC-J. Satellite cell trans-
plantation for myocardial repair: labeling techniques. Transplant
Proc 1994;26(6):3357.
[12] Marelli D, Desrosiers C, el-Alfy M, Kao RL, Chiu RC. Cell
transplantation for myocardial repair: an experimental ap-
proach. Cell Transplant 1992;1(6):383–90.
[13] Zibaitis A, Greentree D, Ma F, Marelli D, Duong M, Chiu
RC-J. Myocardial regeneration with satellite cell implantation.
Transplant Proc 1994;26(6):3294.
[14] Muller-Glauser W, Lehmann KH, Bittmann PO, et al. A compli-
ant small-diameter vascular prosthesis lined with functional
venous endothelial cells. ASAIO Trans 1988;34(3):528–31.
[15] Pasic M, Muller-Glauser W, von Segesser L, Odermatt B,
Lachat M, Turina M. Endothelial cell seeding improves patency
of synthetic vascular grafts: manual versus automatized method.
Eur J Cardiothorac Surg 1996;10(5):372–9.
G. Zu¨nd et al. : European Journal of Cardio-thoracic Surgery 13 (1998) 160–164164
[16] Pasic M, Muller-Glauser W, Odermatt B, Lachat M, Seifert B,
Turina M. Seeding with omental cells prevents late neointimal
hyperplasia in small-diameter Dacron grafts. Circulation
1995;92(9):2605–16.
[17] Pasic M, Muller-Glauser W, von Segesser L, Lachat M, Mi-
haljevic T, Turina M. Superior late patency of small-diameter
Dacron grafts seeded with omental microvascular cells: An ex-
perimental study. Ann Thorac Surg 1994;58:677.
[18] Matsouko H, Furusawa M, Kono A. Growth potential of
human fibroblasts on contact sensitive confluent monolayer fixed
with 3% glutaraldehyde. Gan To Kag R 1994;21:563–4.
[19] Mooney DJ, Organ G, Vacanti JP, Langer R. Design and
fabrication of biodegradable polymer devices to engineer tubular
tissues. Cell Transplant 1994;3(2):203–10.
Appendix A. Conference discussion
Dr T. Ferguson (St. Louis, USA): You caught me a little by
surprise because the abstract does not refer specifically to using this
approach on valves, which to me is the most difficult experimental
environment. I guess my question would be, is this technique applica-
ble to vascular grafts and other biologic situations?
Dr Zund: Yes. I do agree with you. In one of our animal studies we
were just replacing a pulmonary leaflet.
Dr Ferguson: Well, if it works in a valve, it will work anywhere in
the body, of that you can be sure.
Dr C. Muneretto (Padua, Italy): We have already developed a
research program on tissue engineering. And in our experience we use
human vessel treated to suppress host-immune response, and we use
this vessel as a geometrical and mechanical support for the seeding
and growth of fibroblasts and endothelial cells. We found two main
problems. The first one, the endothelial growth; and the second one,
membrana basalis formation.
I have two questions for you. Did you use any method to increase
speed in endothelial cell growth? And second question, did you find
any formation of membrana basalis in you conduit?
Dr Zund: First of all, we don’t use any additional factors for
endothelial growth. We just are culturing them, and then, after some
passages, we are seeding them on the fibroblast core. Second, we were
not yet looking for the basilar membrane.
Dr Ferguson: Were you able to show by low microscopic scans, that
total coverage of the surface is achieved?
Dr Zund: Yes, sir. The fibroblasts were totally confluent and
formed a new tissue.
.
